Science bounties

Produce a traceable evidence map showing how far two published bacterial sensing studies support the Living Medicine concept. The useful result is an explicit boundary between demonstrated sensing, demonstrated therapeutic output, modeling, and unproven claims about autonomous treatment in patients.

Create a decision-ready evidence audit separating the published support for an α2δ-1 decoy peptide from the evidence still needed for Radicular's proposed analgesic. The purchased result is a traceable claim table and a short, evidence-calibrated replacement research rationale.

Audit three primary studies cited by the OpenLabs rhythm project and determine whether they support its proposed interaction between rhythmic synchrony and psychedelic group experience. Deliver a traceable claim audit and a precise account of what its proposed comparison can establish.

Build an evidence-to-claim map showing which parts of the OpenLabs peptide-gel hypothesis are supported by two open QK peptide studies, and which remain untested. The result should let a research sponsor distinguish measured angiogenic effects from assumptions about skin delivery and aging.

Produce a source-auditable evidence brief for Ejochi's proposed Sphenocentrum jollyanum / Eurycoma longifolia blend. Determine what three published studies establish about hormones and reproductive outcomes, and which claims cannot be transferred to the proposed blend.

Create a reusable chemical-occurrence and assay dataset from a published Thai Stephania study, with an explicit taxonomic audit. The Chemical Evolution of Thai Moonseed Family project needs chemical records that can later be joined to phylogenetic data without confusing plant identity, unmeasured activity, and compound absence.

Turn the public PHBV biocomposite proposal into a compact, analysis-ready design specification. The result should expose which observations could support environment-selective degradation and which apparent effects could instead come from sampling, microbial composition, or invalid statistical comparisons. This is design and evidence work; no experimental results exist for this bounty.

Build a traceable comparative evidence dataset that helps Signal Secretome decide what existing experiments do and do not establish about whole mesenchymal stromal-cell secretome versus isolated extracellular vesicles for neuroinflammation. This purchases a bounded analysis of three published studies, not a clinical recommendation or a new experiment.

Build a reproducible endpoint-design calculator from two published RTB101 trials. Quantify how observed event incidence, endpoint composition and baseline-risk uncertainty change the sample size needed for a future randomized trial. This addresses efficacy measurement and planning, separately from adverse-event detection or any claim that mTOR inhibition extends healthy life.

Build a reproducible benchmark comparing simple receptor-signaling models against a mean-only baseline for published mouse head-twitch response magnitude. Test both held-out compounds and transfer between the study's two compound panels. The useful outcome is a bounded decision about what evidence a computational neuropharmacology forecast should require, including a finding that no tested model improves reliably on the baseline.

Build a reproducible shortlist of BCL11A enhancer variants for endogenous functional validation using published saturation-mutagenesis reporter measurements. Quantify how barcode support, multiple testing and effect-size thresholds change the shortlist. A result finding no defensible robust candidates is eligible.

Reanalyze public TAK-925 response curves at OX1R and OX2R to determine when a subtype-selectivity ratio is identifiable and when only a bound or an inconclusive result is justified. Deliver a reproducible quantitative decision aid for interpreting the OX2R-004 program's proposed OX1R counter-screen.